Drug Development Pipeline
Back to the Drug Development Pipeline
Docosahexaenoic Acid (DHA)
Docosahexaenoic acid (DHA) is an omega-3 fatty acid with anti-inflammatory properties.
No further clinical development in CF is planned at this time.
The program was fully funded through the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More